Clinical Role of Serum miR107 in Type 2 Diabetes and Related Risk Factors.

Autor: Šimonienė D; Department of Endocrinology, Lithuanian University of Health Sciences (LUHS), 50161 Kaunas, Lithuania., Stukas D; Laboratory of Surgical Gastroenterology, Institute for Digestive Research, Lithuanian University of Health Sciences (LUHS), 44307 Kaunas, Lithuania., Daukša A; Laboratory of Surgical Gastroenterology, Institute for Digestive Research, Lithuanian University of Health Sciences (LUHS), 44307 Kaunas, Lithuania.; Department of Surgery, Lithuanian University of Health Sciences (LUHS), 50161 Kaunas, Lithuania., Veličkienė D; Department of Endocrinology, Lithuanian University of Health Sciences (LUHS), 50161 Kaunas, Lithuania.; Institute of Endocrinology, Lithuanian University of Health Sciences (LUHS), 44307 Kaunas, Lithuania.
Jazyk: angličtina
Zdroj: Biomolecules [Biomolecules] 2022 Apr 08; Vol. 12 (4). Date of Electronic Publication: 2022 Apr 08.
DOI: 10.3390/biom12040558
Abstrakt: Background: As the diagnostic and treatment options for diabetes improve, more attention nowadays is being paid to the exact identification of the etiopathological mechanism of type 2 diabetes (T2DM). Insulin resistance (IR) is a pathogenetic background for T2DM. Several studies demonstrate that miRNAs play an important role in systemic inflammation and thus in T2DM pathogenesis. Overexpression of miR-107 may cause an imbalance of glucose homeostasis, obesity, and dyslipidemia, by regulating insulin sensitivity through the insulin signaling pathway.
Methods: 53 patients with T2DM and 54 nondiabetic patients were involved in the study. This study aimed to examine whether miR-107 expression in the serum of patients with diabetes was different from the control group (non-diabetic) and whether miR-107 expression correlated with lipid levels, BMI, and other factors, and finally, with insulin resistance in general.
Results: miR-107 expression was higher in the T2DM group than in the control group (1.33 versus 0.63 ( p = 0.016). In general, miR-107 expression was directly and positively associated with BMI ( r = 0.3, p = 0.01), age ( r = 0.3, p = 0.004), and male gender ( p = 0.006). Moreover, miR-107 was related to dyslipidemia: Patients with higher miR-107 levels had lower HDL levels (in the control group: r = -0.262, p = 0.022 vs. diabetic group: r = -0.315, p = 0.007). Finally, the overexpression of miR-107 was associated with higher HOMA-IR in the diabetic group ( r = 0.373, p = 0.035).
Conclusion: MiR-107 expression is higher among diabetic patients than that of nondiabetic control subjects. Higher miR-107 levels are also related to dyslipidemia (lower HDL levels)-in the general cohort and non-diabetic subjects. Moreover, higher miR-107 expression is related to insulin resistance in the diabetic group. In general, higher miR-107 expression levels are related to a higher BMI, older age, and the male gender.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje